Trial Profile
Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2023
Price :
$35
*
At a glance
- Drugs Tumour cell vaccine-GVAX (Primary)
- Indications Carcinoma; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Jul 2012 Actual end date (Aug 2007) added as reported by ClinicalTrials.gov.
- 08 Jun 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 13 Oct 2005 New trial record.